Top

World Journal of Urology

Published in:

01-02-2014 | Invited Review

How far is the horizon? From current targets to future drugs in advanced renal cancer

Authors: Stephan Kruck, Axel S. Merseburger, Arnulf Stenzl, Jens Bedke

Published in: World Journal of Urology | Issue 1/2014

Abstract

Purpose

The proliferative control of renal cell cancer (RCC) via vascular endothelial growth factor and mammalian target of rapamycin inhibition by targeted agents has substantially improved survival rates for RCC patients with metastatic (m) disease. However, the management of mRCC remains challenging because some patients are primarily refractory to the approved targeted agents and most therapies eventually fail because of the development of an intractable drug resistance. Tumor progression is closely related to a persistent or restored proliferation via direct and indirect oncogenic signals. Although the elucidation of cancer cell proliferation in the “–omics era” has revealed an enormous number of new potential targets, a comprehensive overview of the different pathways that might serve as new drug targets has become increasingly complex.

Methods/Results

This review highlights the well-trodden pathways in mRCC that are inhibited by targeting agents and describes innovative modes of action within these pathways that are currently not targeted but are under exploration in clinical studies. Additionally, this paper highlights as future drug targets the components of tumor metabolism that supply the tumor cells with nutrition.

Conclusions

These fundamental insights into RCC proliferation as a key driver of progression are urgently needed to overcome the currently improved but still limited targeted drug success.

Kruck S, Hennenlotter J, Vogel U, Schilling D, Gakis G, Hevler J, Kuehs U, Stenzl A, Schwentner C (2012) Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications. BJU Int 109(4):634–638. doi:10.1111/j.1464-410X.2011.10392.x PubMedCrossRef

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013 PubMedCrossRef

Kruck S, Bedke J, Kuczyk MA, Merseburger AS (2012) Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 12(6):777–785. doi:10.1586/era.12.43 PubMedCrossRef

Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE (2009) Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 15(24):7582–7592. doi:10.1158/1078-0432.ccr-09-2131 PubMedCentralPubMedCrossRef

McCarty G, Awad O, Loeb DM (2011) WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. J Biol Chem 286(51):43634–43643. doi:10.1074/jbc.M111.310128 PubMedCrossRef

Sitaram RT, Degerman S, Ljungberg B, Andersson E, Oji Y, Sugiyama H, Roos G, Li A (2010) Wilms’ tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. Br J Cancer 103(8):1255–1262. doi:10.1038/sj.bjc.6605878 PubMedCentralPubMedCrossRef

Merseburger AS, Hennenlotter J, Kuehs U, Simon P, Kruck S, Koch E, Stenzl A, Kuczyk MA (2008) Activation of PI3 K is associated with reduced survival in renal cell carcinoma. Urol Int 80(4):372–377. doi:10.1159/000132694 PubMedCrossRef

Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408(6810):307–310. doi:10.1038/35042675 PubMedCrossRef

Noon AP, Vlatkovic N, Polanski R, Maguire M, Shawki H, Parsons K, Boyd MT (2010) p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer 116(4):780–790. doi:10.1002/cncr.24841 PubMedCentralPubMedCrossRef

10.

Kruck S, Merseburger AS, Hennenlotter J, Scharpf M, Eyrich C, Amend B, Sievert KD, Stenzl A, Bedke J (2012) High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int 109(10):1565–1570. doi:10.1111/j.1464-410X.2011.10649.x PubMedCrossRef

11.

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732. doi:10.1038/nrc1187 PubMedCrossRef

12.

Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22(24):4991–5004. doi:10.1200/jco.2004.05.061 PubMedCrossRef

13.

Smaldone MC, Maranchie JK (2009) Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urol Oncol 27(3):238–245. doi:10.1016/j.urolonc.2007.12.001 PubMedCrossRef

14.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676. doi:10.1038/nm0603-669 PubMedCrossRef

15.

Baldewijns MM, van Vlodrop IJH, Vermeulen PB, Soetekouw PMMB, van Engeland M, de Bruïne AP (2010) VHL and HIF signalling in renal cell carcinogenesis. J Pathol 221(2):125–138. doi:10.1002/path.2689 PubMedCrossRef

16.

Zha X, Wang F, Wang Y, He S, Jing Y, Wu X, Zhang H (2011) Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res 71(1):13–18. doi:10.1158/0008-5472.can-10-1668 PubMedCrossRef

17.

Godinot C, de Laplanche E, Hervouet E, Simonnet H (2007) Actuality of Warburg’s views in our understanding of renal cancer metabolism. J Bioenerg Biomembr 39(3):235–241. doi:10.1007/s10863-007-9088-8 PubMedCrossRef

18.

Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M (1994) Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54(15):4233–4237PubMed

19.

Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development (Cambridge, England) 125(9):1591–1598

20.

Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18(2):338–340. doi:10.1096/fj.03-0271fje PubMed

21.

Currie MJ, Gunningham SP, Turner K, Han C, Scott PAE, Robinson BA, Chong W, Harris AL, Fox SB (2002) Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol 198(4):502–510. doi:10.1002/path.1228 PubMedCrossRef

22.

Guertin DA, Sabatini DM (2007) Defining the Role of mTOR in cancer. Cancer Cell 12(1):9–22PubMedCrossRef

23.

Kruck S, Bedke J, Hennenlotter J, Ohneseit PA, Kuehs U, Senger E, Sievert KD, Stenzl A (2010) Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression. Oncol Rep 23(1):159–163PubMed

24.

Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126(5):955–968. doi:10.1016/j.cell.2006.06.055 PubMedCrossRef

25.

Janssens N, Janicot M, Perera T (2006) The Wnt-dependent signaling pathways as target in oncology drug discovery. Invest New Drugs 24(4):263–280. doi:10.1007/s10637-005-5199-4 PubMedCentralPubMedCrossRef

26.

Hamanaka RB, Chandel NS (2012) Targeting glucose metabolism for cancer therapy. J Exp Med 209(2):211–215. doi:10.1084/jem.20120162 PubMedCentralPubMedCrossRef

27.

Warburg O (1956) On respiratory impairment in cancer cells. Science (New York, NY) 124(3215):269–270

28.

Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033. doi:10.1126/science.1160809 PubMedCentralPubMedCrossRef

29.

Gerlinger M, Santos CR, Spencer-Dene B, Martinez P, Endesfelder D, Burrell RA, Vetter M, Jiang M, Saunders RE, Kelly G, Dykema K, Rioux-Leclercq N, Stamp G, Patard JJ, Larkin J, Howell M, Swanton C (2012) Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol 227(2):146–156. doi:10.1002/path.4006 PubMedCentralPubMedCrossRef

30.

Parks SK, Chiche J, Pouyssegur J (2011) pH control mechanisms of tumor survival and growth. J Cell Physiol 226(2):299–308. doi:10.1002/jcp.22400 PubMedCrossRef

31.

Bedke J, Gouttefangeas C, Kruck S, Stenzl A (2012) A vaccine in renal cell carcinoma: are we nearing reality? Expert Rev Anticancer Ther 12(12):1503–1505. doi:10.1586/era.12.139 PubMedCrossRef

32.

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867. doi:10.1038/nature01322 PubMedCentralPubMedCrossRef

33.

Eichelberg C, Junker K, Ljungberg B, Moch H (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 55(4):851–863. doi:10.1016/j.eururo.2009.01.003 PubMedCrossRef

34.

Bedke J, Chun FK, Merseburger A, Scharpf M, Kasprzyk K, Schilling D, Sievert KD, Stenzl A, Kruck S (2012) Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy. BJU Int. doi:10.1111/j.1464-410X.2012.11642.x

35.

Huang D, Ding Y, Li Y, Luo W-M, Zhang Z-F, Snider J, VandenBeldt K, Qian C-N, Teh BT (2010) Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70(3):1053–1062. doi:10.1158/0008-5472.can-09-3722 PubMedCrossRef

36.

Motzer RJ (2012) Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma: results of the COMPARZ Trial. ESMO 2012

37.

Motzer RJ, Eisen T, Hutson TE, Szczylik C, Krygowski M, Strahs AL, Esteves B, Krivoshik AP, Berkenblit A, Nosov D (2013) Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma. ASCO Meet Abstr 31(6_suppl):350

38.

http://clinicaltrials.gov/show/NCT00566995

39.

Angevin E, Grunwald V, Ravaud A, Castellano DE, Lin CC, Gschwend JE, Harzstark AL, Chang J, Wang Y, Shi MM, Escudier BJ (2011) A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). ASCO Meet Abstr 29(15_suppl):4551

40.

http://clinicaltrials.gov/show/NCT01223027

41.

Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B (2012) AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 118(24):6152–6161. doi:10.1002/cncr.27632 PubMedCrossRef

42.

http://clinicaltrials.gov/show/NCT00467025

43.

http://clinicaltrials.gov/show/NCT01664182

44.

http://clinicaltrials.gov/show/NCT00982657

45.

Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T, Quinn DI (2012) Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 13(10):1055–1062. doi:10.1016/s1470-2045(12)70364-9 PubMedCrossRef

46.

http://clinicaltrials.gov/show/NCT01727336

47.

Karar J, Cerniglia GJ, Lindsten T, Koumenis C, Maity A (2012) Dual PI3 K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1alpha expression by blocking protein translation and increases cell death under hypoxia. Cancer Biol Ther 13(11):1102–1111. doi:10.4161/cbt.21144 PubMedCrossRef

48.

Toschi A, Lee E, Gadir N, Ohh M, Foster DA (2008) Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 283(50):34495–34499. doi:10.1074/jbc.C800170200 PubMedCrossRef

49.

Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O (2011) Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol cancer 10:90. doi:10.1186/1476-4598-10-90 PubMedCentralPubMedCrossRef

50.

http://clinicaltrials.gov/show/NCT01453595

51.

http://clinicaltrials.gov/show/NCT01442090

52.

Cho DC, Figlin RA, Flaherty KT, Michaelson D, Sosman JA, Ghebremichael M, Bowers ME, Mier JW, Atkins MB, McDermott DF (2009) A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). ASCO Meet Abstr 27(15S):5101

53.

http://clinicaltrials.gov/show/NCT01283048

54.

http://clinicaltrials.gov/show/NCT01239342

55.

Lehmann S, Bykov VJN, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson P-O (2012) Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30(29):3633–3639. doi:10.1200/jco.2011.40.7783 PubMedCrossRef

56.

Madhok BM, Yeluri S, Perry SL, Hughes TA, Jayne DG (2011) Targeting glucose metabolism: an emerging concept for anticancer therapy. Am J Clin Oncol 34(6):628–635. doi:10.1097/COC.0b013e3181e84dec PubMedCrossRef

57.

http://clinicaltrials.gov/show/NCT00741403

58.

http://clinicaltrials.gov/show/NCT01791595

59.

McDonald PC, Winum JY, Supuran CT, Dedhar S (2012) Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 3(1):84–97PubMed

60.

Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J, Hofmann R, Kindler M, Kloepfer P, Stief C (2011) A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 29(1):121–126. doi:10.1007/s00345-010-0570-2 PubMedCrossRef

Title: How far is the horizon? From current targets to future drugs in advanced renal cancer
Authors: Stephan Kruck
Axel S. Merseburger
Arnulf Stenzl
Jens Bedke
Publication date: 01-02-2014
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 1/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-013-1096-1

At a glance: The STEP trials

Springer Medicine

How far is the horizon? From current targets to future drugs in advanced renal cancer

Abstract

Purpose

Methods/Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods/Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Clinical outcomes and patient satisfaction rates among elderly male aged ≥75 years with inflatable penile prosthesis implant for medically refractory erectile dysfunction

d-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial

Categorization of intraoperative ureteroscopy complications using modified Satava classification system

Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group

Open versus robotic-assisted partial nephrectomy: a multicenter comparison study of perioperative results and complications

Peripelvic/periureteral fat invasion is independently associated with worse prognosis in pT3 upper tract urothelial carcinoma